732 related articles for article (PubMed ID: 16051886)
1. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction.
Schulze PC; Fang J; Kassik KA; Gannon J; Cupesi M; MacGillivray C; Lee RT; Rosenthal N
Circ Res; 2005 Sep; 97(5):418-26. PubMed ID: 16051886
[TBL] [Abstract][Full Text] [Related]
2. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.
Sandri M; Sandri C; Gilbert A; Skurk C; Calabria E; Picard A; Walsh K; Schiaffino S; Lecker SH; Goldberg AL
Cell; 2004 Apr; 117(3):399-412. PubMed ID: 15109499
[TBL] [Abstract][Full Text] [Related]
3. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.
Stitt TN; Drujan D; Clarke BA; Panaro F; Timofeyva Y; Kline WO; Gonzalez M; Yancopoulos GD; Glass DJ
Mol Cell; 2004 May; 14(3):395-403. PubMed ID: 15125842
[TBL] [Abstract][Full Text] [Related]
4. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy.
Glass DJ
Nat Cell Biol; 2003 Feb; 5(2):87-90. PubMed ID: 12563267
[TBL] [Abstract][Full Text] [Related]
5. Chromium supplement inhibits skeletal muscle atrophy in hindlimb-suspended mice.
Dong F; Hua Y; Zhao P; Ren J; Du M; Sreejayan N
J Nutr Biochem; 2009 Dec; 20(12):992-9. PubMed ID: 19071005
[TBL] [Abstract][Full Text] [Related]
6. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression.
Yoshida T; Semprun-Prieto L; Sukhanov S; Delafontaine P
Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1565-70. PubMed ID: 20228261
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading.
Nakao R; Hirasaka K; Goto J; Ishidoh K; Yamada C; Ohno A; Okumura Y; Nonaka I; Yasutomo K; Baldwin KM; Kominami E; Higashibata A; Nagano K; Tanaka K; Yasui N; Mills EM; Takeda S; Nikawa T
Mol Cell Biol; 2009 Sep; 29(17):4798-811. PubMed ID: 19546233
[TBL] [Abstract][Full Text] [Related]
8. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Xu J; Li R; Workeneh B; Dong Y; Wang X; Hu Z
Kidney Int; 2012 Aug; 82(4):401-11. PubMed ID: 22475820
[TBL] [Abstract][Full Text] [Related]
9. Skeletal muscle hypertrophy and atrophy signaling pathways.
Glass DJ
Int J Biochem Cell Biol; 2005 Oct; 37(10):1974-84. PubMed ID: 16087388
[TBL] [Abstract][Full Text] [Related]
10. Signaling pathways perturbing muscle mass.
Glass DJ
Curr Opin Clin Nutr Metab Care; 2010 May; 13(3):225-9. PubMed ID: 20397318
[TBL] [Abstract][Full Text] [Related]
11. Signalling pathways regulating muscle mass in ageing skeletal muscle: the role of the IGF1-Akt-mTOR-FoxO pathway.
Sandri M; Barberi L; Bijlsma AY; Blaauw B; Dyar KA; Milan G; Mammucari C; Meskers CG; Pallafacchina G; Paoli A; Pion D; Roceri M; Romanello V; Serrano AL; Toniolo L; Larsson L; Maier AB; Muñoz-Cánoves P; Musarò A; Pende M; Reggiani C; Rizzuto R; Schiaffino S
Biogerontology; 2013 Jun; 14(3):303-23. PubMed ID: 23686362
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms involved in 3',5'-cyclic adenosine monophosphate-mediated inhibition of the ubiquitin-proteasome system in skeletal muscle.
Gonçalves DA; Lira EC; Baviera AM; Cao P; Zanon NM; Arany Z; Bedard N; Tanksale P; Wing SS; Lecker SH; Kettelhut IC; Navegantes LC
Endocrinology; 2009 Dec; 150(12):5395-404. PubMed ID: 19837877
[TBL] [Abstract][Full Text] [Related]
13. IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3beta pathways and inhibition of atrogin-1 mRNA.
Dehoux M; Gobier C; Lause P; Bertrand L; Ketelslegers JM; Thissen JP
Am J Physiol Endocrinol Metab; 2007 Jan; 292(1):E145-50. PubMed ID: 16926385
[TBL] [Abstract][Full Text] [Related]
14. Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in response to formoterol administration in rat skeletal muscle.
Joassard OR; Amirouche A; Gallot YS; Desgeorges MM; Castells J; Durieux AC; Berthon P; Freyssenet DG
Int J Biochem Cell Biol; 2013 Nov; 45(11):2444-55. PubMed ID: 23916784
[TBL] [Abstract][Full Text] [Related]
15. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy.
Glass DJ
Curr Top Microbiol Immunol; 2010; 346():267-78. PubMed ID: 20593312
[TBL] [Abstract][Full Text] [Related]
16. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting.
Song YH; Li Y; Du J; Mitch WE; Rosenthal N; Delafontaine P
J Clin Invest; 2005 Feb; 115(2):451-8. PubMed ID: 15650772
[TBL] [Abstract][Full Text] [Related]
17. Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy.
Léger B; Cartoni R; Praz M; Lamon S; Dériaz O; Crettenand A; Gobelet C; Rohmer P; Konzelmann M; Luthi F; Russell AP
J Physiol; 2006 Nov; 576(Pt 3):923-33. PubMed ID: 16916907
[TBL] [Abstract][Full Text] [Related]
18. Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1.
Léger B; Vergani L; Sorarù G; Hespel P; Derave W; Gobelet C; D'Ascenzio C; Angelini C; Russell AP
FASEB J; 2006 Mar; 20(3):583-5. PubMed ID: 16507768
[TBL] [Abstract][Full Text] [Related]
19. XIAP reduces muscle proteolysis induced by CKD.
Hu J; Du J; Zhang L; Price SR; Klein JD; Wang XH
J Am Soc Nephrol; 2010 Jul; 21(7):1174-83. PubMed ID: 20431038
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy in mice via its receptor, Mas.
Morales MG; Abrigo J; Acuña MJ; Santos RA; Bader M; Brandan E; Simon F; Olguin H; Cabrera D; Cabello-Verrugio C
Dis Model Mech; 2016 Apr; 9(4):441-9. PubMed ID: 26851244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
